FDA Approves Fiasp for Children With Diabetes

The FDA has approved insulin aspart injection (Fiasp, Novo Nordisk), 100 U/mL, as a new mealtime option for children with diabetes—the first fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation.

Diabetes is one of the most common chronic conditions of childhood, with nearly 18,000 new cases of type-1 diabetes diagnosed each year. Managing diabetes can be challenging for parents and caregivers because it is hard to know exactly how much or how quickly children will eat, making mealtime insulin dosing difficult. Conventional rapid-acting insulins must be administered ahead of meals, which requires some guesswork to dose properly, and children with diabetes may not achieve adequate blood sugar control.

More here –>

Print Friendly, PDF & Email